Abstracts tagged "Antibodies"

Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Naizhuo Zhao ¹, Audrey Smargiassi ², Marianne Hatzopoulou ³, Ines Colmegna ⁴, Marie Hudson ⁵, Marvin Fritzler ⁶, Philip Awadalla ⁷ and Sasha Bernatsky⁸, ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²University of Montreal, Montreal, Canada, ³University of Toronto, Toronto, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁷Ontario Institute for Cancer Research, Toronto, Canada, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
Abstract Number: 109 • 2019 ACR/ARP Annual Meeting
Targeting CD6 Expression Attenuates T Cell Activity in Murine Collagen Induced Arthritis
Yan Li ¹, Jeffrey H. Ruth ², Stephanie Rasmussen ³, Kalana S. Athukorala ², Daniel P. Weber ², M. Asif Amin ², Phillip Campbell ³, Nora Singer ⁴, David Fox⁵ and Feng Lin ¹, ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁴The MetroHealth System -Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence,University of Michigan, Ann Arbor, MI
Background/Purpose: CD6, an important regulator of T cell function, interacts with the ligands CD166 and CD318. We previously examined CD318 expression on synovial tissues (STs)…
Abstract Number: 964 • 2019 ACR/ARP Annual Meeting
Identifying Jo-1-Specific B Cells in the Primary Immune Repertoire in Idiopathic Inflammatory Myopathies
Jennifer Young-Glazer¹, Erin Wilfong ², Peggy Kendall ¹, Rachel Bonami ¹ and Leslie Crofford ², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting
New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Sho Sasaki¹, Akira Ishii ², Mai Sugiyama ², Yuto Izumi ², Yoko Nakagome ², Kazuki Hirano ³, Takayoshi Kurabayashi ¹, Shinichi Nogi ⁴, Noriko Sasaki ², Chiho Yamada ² and Shinji Sato ⁵, ¹Tokai Universitiy School of Medicine, Isehara, Japan, ²Tokai University School of Medicine, Isehara, Japan, ³Tokai University School of Medicine, Isehara, ⁴National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan
Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…
Abstract Number: 1288 • 2019 ACR/ARP Annual Meeting
Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice
Fergus To¹, Clara Ventín Rodríguez ², Shuayb Elkhalifa ³, James Lilleker ⁴ and Hector Chinoy ⁴, ¹University of British Columbia, Vancouver, Canada, ²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³(3) Department of Immunology, Salford Royal NHS Foundation, Salford, United Kingdom, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: To evaluate the real-world accuracy of a line blot immunoassay (LIA) for myositis-specific (MSA) and myositis-associated (MSA) autoantibody testing in patients at a tertiary…
Abstract Number: 1343 • 2018 ACR/ARHP Annual Meeting
A Novel Autoantibody Against DNA Damage Binding Protein-1 in Idiopathic Inflammatory Myopathy
Yuji Hosono^1,2, Ran Nakashima¹, Koji Kitagori¹, Kosaku Murakami¹, Hajime Yoshifuji¹, Koichiro Ohmura³ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Many kinds of autoantibodies are detected in idiopathic inflammatory myopathy (IIM) patients. Some of them are useful to diagnose, predict the clinical course, and…
Abstract Number: 1344 • 2018 ACR/ARHP Annual Meeting
Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States
Yuji Hosono¹, Iago Pinal-Fernandez¹, Katherine Pak¹, Jemima Albayda², Eleni Tiniakou³, Julie J. Paik⁴, Christopher A. Mecoli⁵, Sonye K. Danoff⁶, Lisa Christopher-Stine⁶ and Andrew Mammen^1,7, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibodies are common among Japanese dermatomyositis (DM) and clinically amyopathic DM (CADM) patients who develop rapidly progressive interstitial lung…
Abstract Number: 1551 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies to Certolizumab Pegol Are Assiciated with Low Drug Levels and Reduced Clinical Response at 3 Months in Patients with Inflammatory Joint Diseases
Johanna Gehin¹, Guro Løvik Goll², Silje Watterdal Syversen², David J Warren¹, Joseph Sexton³, Eldri Kvein Strand⁴, Tore Kvien⁵, Elisabeth Lie² and Nils Bolstad⁶, ¹Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Lillehammer Revmatismesykehus, Lillehammer, Norway, ⁵NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁶Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway
Background/Purpose: Anti-drug antibodies (ADAb) to biological drugs predispose patients (pts) to low drug levels and lack of treatment response. For certolizumab pegol (CP) knowledge about…
Abstract Number: 1741 • 2018 ACR/ARHP Annual Meeting
Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Voon H. Ong³ and Christopher P. Denton⁴, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: Although severity of skin involvement and change in skin thickness over time vary substantially between patients with diffuse cutaneous systemic sclerosis (dcSSc), for the…
Abstract Number: 1742 • 2018 ACR/ARHP Annual Meeting
Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Anna Leslie³, Voon H. Ong⁴ and Christopher P. Denton⁵, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Division of Medicine, University College London, London, United Kingdom, ⁵University College London, London, United Kingdom
Background/Purpose: Pulmonary fibrosis (PF) is a leading cause of disease-related death in SSc patients. Some studies suggest that the timing of PF development differs between…
Abstract Number: 1898 • 2018 ACR/ARHP Annual Meeting
Type I Interferon-Induced Proteins May Facilitate the Occurrence of Long QT Syndrome (LQTS) in Parallel with Anti-Ro/SSA and Anti-Ro52/TRIM21 Antibody Levels in Patients with Systemic Lupus Erythematous (SLE): A Bench to Bedside Approach
Luis F. Perez-Garcia^1,2, Irving O. Estevez-Garcia³, Ricardo Marquez-Velasco³, Pedro Iturralde⁴, Luis H. Silveira⁵ and Luis M. Amezcua-Guerra^2,6,7, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁴Cardiology - Electrophysiology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁵Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ⁶Cardiovascular Research Laboratory, Unidad de Investigacion Traslacional, Universidad Nacional Autonoma de Mexico/Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁷Department of Health Care, Universidad Autonoma Metropolitana, Xochimilco, Mexico City, Mexico
Background/Purpose: Long QT syndrome (LQTS) is an abnormal QT corrected (QTc) interval prolongation, strongly associated with increased risk of sudden death. Studies have associated LQTS…
Abstract Number: 2118 • 2018 ACR/ARHP Annual Meeting
Prevalence of Acquired Activated Protein C Resistance and Anti-Protein C Antibodies in Systemic Lupus Erythematosus
Giuseppe Alvise Ramirez^1,2,3,4, Hannah Cohen^5,6, David A. Isenberg^4,7 and Maria Efthymiou⁵, ¹Università Vita-Salute San Raffaele, Milan, Italy, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁴Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁵Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ⁶Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁷University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterised by increased cardiovascular risk, with a 5-20 fold increased risk for venous thromboembolism (VTE)…
Abstract Number: 2576 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis
Christopher T. Ritchlin¹, Joseph F. Merola², Amanda M. Gellett³, Chen-Yen Lin³ and Talia Muram³, ¹University of Rochester Medical Center, Rochester, NY, ²Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Anti-drug antibody (ADA) development can potentially affect the efficacy of biologics; concomitant MTX decreases the development of ADA for some biologics.1 Ixekizumab (IXE), a…
Abstract Number: 168 • 2018 ACR/ARHP Annual Meeting
IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Elena Rubini³, Ana Suárez⁴, Dario Roccatello⁵, Savino Sciascia⁶ and Javier Rodríguez-Carrio⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose: Reliable biomarkers for risk stratification in Antiphospholipid Syndrome (APS) are still lacking. Anti-high-density lipoproteins antibodies (anti-HDL) showed promising results in predicting the development of…
Abstract Number: 2682 • 2018 ACR/ARHP Annual Meeting
Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus
Yu-Min Kuo^1,2, Jenhao Chen³, Jean-san Chia⁴, Chiau-jing Jung⁵ and Song-Chou Hsieh⁶, ¹Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ³Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital,Yunlin branch, Yunlin County, Taiwan, ⁴Graduate Institute of Immunology, National Taiwan University College of Medicine, Taipei, Taiwan, ⁵Department of Microbiology and Immunology, School of Medicine,, College of Medicine, Taipei Medical University, Taipei, Taiwan, ⁶National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Streptoccocal infections can cause rheumatic fever sharing clinical presentations similar to SLE. Whether oral commensal streptococci could induce cross-reactive and pathogenic antibodies remained unknown.…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.